Navigation Links
Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007
Date:11/20/2007

HAIFA, Israel, November 20 /PRNewswire-FirstCall/ --

- Third quarter Consolidated Net Income NIS 178 Million, Compared to NIS 24 Million Last Year; Third Quarter 2006 Results Adversely Affected by Northern Hostilities

- Company Publishing Today Hebrew Draft Prospectus for the Issue of Debentures Primarily for the Financing of the Strategic Plan; Debentures Were Rated AA Stable by Maalot, a Standard and Poor's Affiliation

Oil Refineries Ltd. (TASE: ORL) ("Oil Refineries" or the "Company") announced today its financial results for three and nine-month periods ending September 30, 2007.

The reported results for the third quarter and nine months 2007 exclude the results of Ashdod Refineries, which was sold at the end of the third quarter 2006, and which generated a substantial capital gain in the said third quarter. The results for the comparable period, the third quarter and nine months of 2006, are pro-forma figures and refer to the consolidated pro-forma statements.

Third Quarter Highlights

- Refining margin USD/bbl 5.7, compared to USD/bbl 7.3 in the third quarter 2006

- Company refining margin 52% higher than Mediterranean Ural Cracking Margin average of USD/bbl 3.75

- Consolidated EBITDA totaled NIS 326, compared to NIS 144 million in third quarter 2006

- Consolidated net income totaled NIS 178 million, compared to 24 million in third quarter 2006

- Quarterly results positively affected by the changes in the USD against the Israeli Shekel; Last year's third quarter results were negatively affected by the northern hostilities

Third Quarter Results

Refining margin for the third quarter totaled USD/bbl 5.7 (USD/MT 41.6), compared to the third quarter Mediterranean Ural Cracking Margin(i) average of USD/bbl 3.75(i) (USD/MT 27.4). Refining margin for the third quarter 2006 totaled USD/bbl 7.3 (USD/MT 52.9).

Consolidated EBITDA for the third quarter 2007 reached NIS 326 million, compare
'/>"/>

SOURCE Oil Refineries Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... highlights for the three and six month ... experienced a strong second quarter with the ... therapy treatment in,refractory head and neck cancer ...
... DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter 2008,financial results after the NASDAQ Global Market ... Jack Lief, Arena,s President and Chief,Executive Officer, and ... Financial Officer, will host a conference call at ...
... Abt Associates has been,ranked 19th in the Marketing News ... Research firms. The listing is based on 2007 revenue ... for,calendar 2007 was $55.1 million. Total company revenues for ... Abt Associates market research activities are carried out ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 9Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 10Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 11Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 12Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 13Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 14Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 15Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 16Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 17Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 18Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 19Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 20Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 21Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 22Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 23Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 24Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 25Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 26Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 27Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 28Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 29Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 30Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 31Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 32Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 33Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... one of the most important prerequisites for a positive self ... rather than the exception that children and young people are ... or subject to bullying are particularly critical of their appearance ... long period. This is revealed in a new thesis in ...
... Prevention (CDC) today released new infection control recommendations ... (KPC)-Producing Organisms, one of the most ... that infections with these highly resistant bacteria are ... In Guidance for Control of Infections with Carbapenem-Resistant ...
... the media. A new study by Dr. Yaniv Levyatan ... of Israel,s National Security College, describes how our side ... "Information warfare" plays a crucial role in ... conventional weapons. Therefore, the information warfare against terrorist organizations ...
Cached Biology News:Children who are dissatisfied with their appearance often have problems with their peer group 2Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: